Professor of Colorectal Surgical Oncology
University of Glasgow
University of Glasgow
Glasgow, Scotland, United Kingdom
Campbell Roxburgh is Professor of Colorectal Surgical Oncology at the University of Glasgow. He trained in Scotland before undertaking a clinical fellowship in colorectal surgical oncology at Memorial Sloan Kettering Cancer Centre. His research interests include clinical and translational rectal cancer research and clinical trials.
He has a leading role in several UK colorectal cancer trials. He is the protocol lead for each of the Dostarlimab immunotherapy arms of FOxTROT colon cancer phase II neoadjuvant trial platform (FT5 and FT6). He is also the chief investigator of the recently completed UK phase II PRIME-RT trial evaluating the addition of anti-PDL1 (Durvalumab) to extended neoadjuvant strategies in rectal cancer. His laboratory group focuses on the interrogation of a novel cohort of serial tumour samples collected in and out of rectal cancer trials. He leads the rectal cancer workstream in the CRUK-funded CRC STARS consortium.
His clinical interests include minimally invasive/ robotic cancer surgery in addition to surgery for locally advanced or recurrent disease and organ preservation in rectal cancer. Between 2019-2024, he held a lead role in the National Robotic Assisted Surgery Framework in NHS Scotland, a national planning process to develop and deploy multi-speciality robotic surgery across Scotland. He now chairs the Scottish National Robotic-Assisted Surgery Audit Group (SRASA) which seeks to develop and maintain standards across NHS Scotland.
Disclosure information not submitted.
Saturday, May 9, 2026
3:07 PM - 3:15 PM ET
Monday, May 11, 2026
1:41 PM - 1:46 PM ET
Novel Predictors of Treatment Response in Rectal Cancer
Tuesday, May 12, 2026
12:10 PM - 12:20 PM ET